Innovation, regulatory policy, and demographics are driving healthcare stocks higher. Healthcare companies have also posted strong first-quarter results.

Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.

Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in the Plenary Session and ASCO press program Investigator-initiated study of Verzenio (abemaciclib) in patients with advanced dedifferentiated liposarcoma also selected for the Plenary Session Kelonia Therapeutics, which Lilly has agreed to acquire, will present updated data for its BCMA-targeted in vivo CAR-T therapy in patients with relapsed and refractory multiple myeloma  Additional Lilly presentations include the first clinical results for an investigational ADC targeting Nectin-4 in patients with advanced urothelial carcinoma and data from programs across lung, breast and blood cancers   INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the details of presentations from across its oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2 in Chicago, Illinois. Data at ASCO include two Plenary Session presentations, featuring primary event-free survival results from the Phase 3 LIBRETTO-432 study of adjuvant Retevmo (selpercatinib) in rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) and an investigator-initiated Phase 3 study, SARC041, evaluating Verzenio (abemaciclib) in patients with advanced dedifferentiated liposarcoma.

Patients lost up to 85 pounds in a study of Eli Lilly's next-generation weight-loss drug, the company said Thursday.

Eli Lilly (NYSE:LLY | LLY Price Prediction) is growing like a software company.

Eli Lilly dominates the weight loss drug market and competes with fellow pharma giant Novo Nordisk. Viking is studying promising weight loss candidates in late-stage trials.

An investigational drug developed by Eli Lilly delivered clinically meaningful weight loss in a trial, the company said as it looks expand its obesity treatment portfolio amid soaring demand.

Eli Lilly said on Thursday that its experimental drug retatrutide helped patients diagnosed with obesity lose more than 28% of their weight over a year and a half in a ​key trial that helps pave the way for the firm to seek regulatory approval and ‌launch the drug next year.

Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses.  The results bring Lilly one step closer to filing for approval of the weekly injection, called retatrutide, which works differently from existing injections and pills.

In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥ 30% weight loss, a level long associated with bariatric surgery Individuals with a baseline BMI ≥ 35 who participated in a study extension continued to lose weight, and achieved up to an average of 85.0 lbs (30.3%) weight loss at 104 weeks  At the 4 mg dose, reached with only a single escalation step, participants lost an average of 47.2 lbs (19.0%) at 80 weeks with a lower observed discontinuation rate due to adverse events vs. placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes.